Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03876002 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
A Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03876002 is a Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 23 participants.
The verdict
NCT03876002, a Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to evaluate microglial activation in the brain using \[18F\]PBR06 in patients with amyotrophic lateral sclerosis (ALS).
Interventions
- DRUG [18F]PBR06
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-06-28 |
| Est. Completion | 2018-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03876002
The ClinicalTrials.gov registry entry for NCT03876002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]PBR06 is the first listed.
NCT03876002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03876002 about?
NCT03876002 is a clinical study titled "Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET". The overall goal of this protocol is to evaluate microglial activation in the brain using \[18F\]PBR06 in patients with amyotrophic lateral sclerosis (ALS).
What is the current status of trial NCT03876002?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-06-28. Estimated completion is 2018-02-07.
What interventions are being tested in trial NCT03876002?
The interventions under investigation include: [18F]PBR06 (DRUG).
Who is sponsoring clinical trial NCT03876002?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.